MK5172 is a potent inhibitor of the hepatitis C virus (HCV) NS3/4A protease, making it a key component in antiviral therapy. It is primarily used in the treatment of chronic hepatitis C infection, particularly in combination with other direct-acting antivirals. Its high barrier to resistance and effectiveness against multiple HCV genotypes enhance its therapeutic value. MK5172 helps suppress viral replication, leading to improved liver function and higher rates of sustained virologic response, which is considered a cure in many patients. Due to its role in combination regimens, it contributes to shorter treatment durations and reduced side effects compared to older interferon-based therapies.